Rheumatology Book

http://www.fpnotebook.com/

Antinuclear Antibody

Aka: Antinuclear Antibody, Antinuclear Antigen, ANA
Advertisement
  1. Negative
    1. Normal titer less than 1:20 dilution
    2. See interpretation below regarding titers
  2. Positive
    1. Normal patient without underlying abnormality: 3-30%
      1. More common in older women
    2. Rheumatologic Conditions
      1. Systemic Lupus Erythematosus
      2. Rheumatoid Arthritis
      3. Mixed connective tissue disease
      4. Sjogren's Syndrome
      5. Necrotizing Vasculitis
    3. Infection
      1. Tuberculosis
      2. Chronic active hepatitis
      3. Subacute Bacterial Endocarditis
      4. HIV Infection
    4. Miscellaneous Conditions
      1. Type I Diabetes Mellitus
      2. Multiple Sclerosis
      3. Pulmonary fibrosis
      4. Silicone gel implants
      5. Pregnant women
      6. Elderly patients
    5. Medications (Drug induced Lupus Erythematosus)
      1. Phenytoin
      2. Ethosuximide
      3. Primidone
      4. Methyldopa
      5. Hydralazine
      6. Penicillamine
      7. Carbamazepine
      8. Procainamide
      9. Thiazides
      10. Griseofulvin
      11. Chlorpromazine
      12. Isoniazid
      13. Quinidine
      14. Gold Salts
      15. Minocycline
  3. Mechanism
    1. IgG or IgM Antinuclear Antibody (ANA)
    2. Binds to nuclei or nuclear components
  4. Screening
    1. Slide test
    2. Uses fixed and permeabilized human HEp-2 cells
    3. Measures direct binding
      1. Patient's serum antibodies to cell nuclei
      2. Specific components of cell nucleus are also bound
        1. See ANA subunits below
  5. Interpretation: Titer (Dilution)
    1. Pretest probability affects interpretation
      1. Primary Care Setting: 2% SLE probability
      2. Rheumatology Setting: 30% SLE probability
    2. Low Positive (1:160 or lower): Low significance
      1. SLE Likelihood: <2% (<26% for rheumatologists)
    3. High Positive (1:320 or higher): Higher significance
      1. SLE Likelihood: 2-17% (32-81% for rheumatologists)
    4. References
      1. Malleson (1997) Arch Dis Child 77:299-304 [PubMed] (or open in [QxMD Read])
  6. Interpretation: ANA Staining Patterns
    1. Systemic Lupus Erythematosus specific patterns
      1. ANA Rim Pattern
      2. ANA Homogenous Pattern
    2. CREST Syndrome and Scleroderma Specific Patterns
      1. ANA Nucleolar Pattern
      2. ANA Centromere Pattern
    3. Non-Specific Patterns
      1. ANA Speckled Pattern
      2. ANA Diffuse Pattern
  7. Interpretation: ANA Subunits
    1. Systemic Lupus Erythematosus
      1. Anti-dsDNA (Lupus sensitivity: 60%)
        1. Specific for lupus erythematosus
        2. Associated with Lupus Nephritis
        3. Associated with Lupus CNS Involvement
      2. Anti-Smith or Anti-Sm (Lupus sensitivity: 20-30%)
        1. Highly specific for lupus erythematosus
      3. Anti-ribosomal P (Lupus sensitivity: 20-30%)
        1. Highly specific for lupus erythematosus
        2. Associated with Lupus Psychosis
      4. Anti-RNP (Lupus sensitivity: 30-40%)
        1. Associated with lupus disease activity
        2. Seen in all cases mixed connective tissue disease
    2. CREST and Scleroderma
      1. Anti-centromere
        1. Sensitivity for Scleroderma: 22-36%
      2. Scl-70 kD kinetochore (Anti-Topoisomerase I)
        1. Sensitivity for Scleroderma: 22-40%
    3. Polymyositis and Dermatomyositis
      1. Anti-Jo1 (sensitivity: 30%)
        1. Also in Raynaud's Phenomenon, pulmonary fibrosis
      2. Anti-Ku
      3. Anti-Mi2
    4. Non-specific
      1. Anti-histone
        1. Drug-Induced Lupus sensitivity: 90%
        2. Systemic Lupus Erythematosus sensitivity: 50%
      2. Anti-Ro (Anti-SSA)
        1. Sjogren's Syndrome sensitivity: 75%
        2. Systemic Lupus Erythematosus sensitivity: 40%
      3. Anti-La (Anti-SSB)
        1. Sjogren's Syndrome sensitivity: 40%
        2. Systemic Lupus Erythematosus sensitivity: 10-15%
      4. Anti-ssDNA
        1. Non-specific and rarely indicated
  8. References
    1. Gladman in Klippel (1997) Rheumatic Diseases p. 255-6
    2. Peng in Ruddy (2001) Kelley's Rheumatology, p. 161-72
    3. Callegari (1995) Postgrad Med, 97(4):65-74 [PubMed] (or open in [QxMD Read])
    4. Lane (2002) Am Fam Physician 65(6):1073-80 [PubMed] (or open in [QxMD Read])

Antibodies, Antinuclear (C0003243)

Definition (NCI) An autoimmune antibody that is directed against structures within the nucleus of the cell.
Definition (MSH) Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.
Definition (CSP) autoimmune, pathological antibodies against histones, DNA, nuclear RNA, or other components of the cell nucleus.
Concepts Amino Acid, Peptide, or Protein (T116) , Immunologic Factor (T129)
MSH D000974
SnomedCT 45530001, 165849001
English Antibodies, Antinuclear, Antibody, Antinuclear, Antinuclear Antibodies, Antinuclear Antibody, Antinuclear Factor, Antinuclear Factors, Factor, Antinuclear, Factors, Antinuclear, antinuclear autoantibody, ANTINUCLEAR ANTIBODIES, Antinuclear antibody (ANA), Antinuclear factor (ANF), ANTINUCLEAR FACTOR, antinuclear antibody, antiDNA autoantibody, antinuclear factor, C25-C27 ANTINUCLEAR ANTIBODIES, Antinuclear Autoantibody, Antibodies, Antinuclear [Chemical/Ingredient], antinuclear antibody (ANA), anti-nuclear antibody, antinuclear factors, antinuclear antibodies, antinuclear antibody ana, ana, ANF, ANA, ANA - Anti-nuclear antibody, ANF - Anti-nuclear factor, Anti-nuclear antibody, Antinuclear antibody, Antinuclear factor, Antinuclear antibody (substance), Anti-nuclear factor, Anti nuclear factor
Swedish Antinukleära antikroppar
Czech protilátky antinukleární
Spanish Antinuclear antibody, Anti nuclear factor, Anti-nuclear antibody, Anti-nuclear factor, FAN, anticuerpo antinuclear (sustancia), anticuerpo antinuclear, factor antinuclear, Anticuerpos Antinucleares, Factores Antinucleares
Finnish Tumavasta-aineet
Italian Fattore antinucleare, Anticorpo antinucleare, Fattori antinucleari, Anticorpi antinucleari
Russian ANTINUKLEARNYE FAKTORY, ANTI-DNK ANTITELA, ANTITELA ANTI-DNK, ANTITELA ANTINUKLEARNYE, FLIUORESTSENTNYE ANTINUKLEARNYE ANTITELA, ANTINUKLEARNYE ANTITELA, АНТИ-ДНК АНТИТЕЛА, АНТИНУКЛЕАРНЫЕ АНТИТЕЛА, АНТИНУКЛЕАРНЫЕ ФАКТОРЫ, АНТИТЕЛА АНТИ-ДНК, АНТИТЕЛА АНТИНУКЛЕАРНЫЕ, ФЛЮОРЕСЦЕНТНЫЕ АНТИНУКЛЕАРНЫЕ АНТИТЕЛА
French ANTICORPS ANTINUCLEAIRES, Facteurs lupiques, Anticorps anti-nucléaires, Anticorps antinucléaires, Facteurs antinucléaires, Facteurs anti-nucléaires, Anticorps antinucléaire, Anticorps anti-nucléaire, ACAN, FAN (Facteur AntiNucléaire)
Portuguese FACTOR ANTINUCLEAR, Anticorpos Antinucleares, Fatores Antinucleares
Japanese 抗体-抗核, 抗DNA抗体, 抗核因子, 蛍光抗核抗体, 抗核抗体
Croatian ANTITIJELA, ANTINUKLEARNA
Polish Przeciwciała przeciwjądrowe, Czynniki przeciwjądrowe
German Antikörper, antinukleäre, Antinukleäre Antikörper, Antinukleäre Faktoren
Sources
Derived from the NIH UMLS (Unified Medical Language System)


You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree